Seres Therapeutics Inc
MCRB
NASDAQ
Biotechnology
$4.54
USD
+0.06 (+1.34%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $44.93M
Volume 37.3K
Revenue
$1.88M
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-22.46M
TTM
-126.1%
YoY
Operating Cash Flow
$-51.26M
TTM
+14.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.4 | 0.4 | 0.4 | 0.7 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.4 | 0.4 | 0.4 | 0.7 |
Selling, General & Administrative | 10.3 | 9.5 | 7.5 | 8.1 | 7.1 |
Other Operating Expenses | 1.7 | 0.7 | 0.6 | 0.0 | 5.8 |
Total Operating Expenses | 24.9 | 22.8 | 19.8 | 21.3 | 22.0 |
Operating Income | -24.9 | -22.5 | -19.4 | -20.9 | -21.3 |
EBITDA | -23.8 | -21.4 | -18.4 | -20.1 | -14.8 |
Other Income / Expense | 4.5 | 30.1 | 3.6 | 0.7 | 25.7 |
Total Other Income / Expense | 5.0 | 30.7 | 4.0 | 1.0 | 25.9 |
Income Before Income Taxes | -19.9 | 8.2 | -15.3 | -19.9 | 4.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -19.9 | 8.2 | -15.3 | -19.9 | 4.6 |
Consolidated Net Income / Loss | -19.9 | 8.2 | -15.3 | -19.9 | 4.6 |
Net Income Attributable to Common Shareholders | -19.9 | 8.2 | -15.3 | -19.9 | 4.6 |
Basic EPS | -$2.27 | $0.94 | -$1.66 | -$2.08 | $0.47 |
Diluted EPS | -$2.27 | $0.94 | -$1.66 | -$2.08 | $0.47 |
Basic Shares Outstanding | 8.7M | 8.8M | 9.2M | 9.6M | 9.7M |
Diluted Shares Outstanding | 8.7M | 8.8M | 9.2M | 9.6M | 9.7M |